Sign up to access all valuation multiples
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
2020
63
LTM Revenue $3.0M
LTM EBITDA -$101M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, AtaiBeckley reported last 12-month revenue of $3.0M and EBITDA of -$101M.
In the same period, AtaiBeckley achieved -$144M in LTM net income.
See AtaiBeckley valuation multiples based on analyst estimatesIn the most recent fiscal year, AtaiBeckley reported revenue of $0.3M and EBITDA of -$145M.
AtaiBeckley expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AtaiBeckley valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$101M | XXX | -$145M | XXX | XXX | XXX |
| EBITDA Margin | -3367% | XXX | -47016% | XXX | XXX | XXX |
| EBIT | -$103M | XXX | -$102M | XXX | XXX | XXX |
| EBIT Margin | -3439% | XXX | -33171% | XXX | XXX | XXX |
| Net Profit | -$144M | XXX | -$149M | XXX | XXX | XXX |
| Net Margin | -4802% | XXX | -48464% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $6.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AtaiBeckley has current market cap of $1.4B, and EV of $1.2B.
As of January 15, 2026, AtaiBeckley's stock price is $4.
See AtaiBeckley trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.4B | XXX | XXX | XXX | XXX | $-0.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAtaiBeckley's trades at 412.4x EV/Revenue multiple, and -12.2x EV/EBITDA.
See valuation multiples for AtaiBeckley and 15K+ public compsAs of January 15, 2026, AtaiBeckley has market cap of $1.4B and EV of $1.2B.
Equity research analysts estimate AtaiBeckley's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AtaiBeckley has a P/E ratio of -9.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 412.4x | XXX | 412.4x | XXX | XXX | XXX |
| EV/EBITDA | -12.2x | XXX | -12.2x | XXX | XXX | XXX |
| EV/EBIT | -12.0x | XXX | -12.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.4x | XXX | -9.4x | XXX | XXX | XXX |
| EV/FCF | -14.8x | XXX | -14.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtaiBeckley's last 12 month revenue growth is -85%
AtaiBeckley's revenue per employee in the last FY averaged $5K, while opex per employee averaged $1.6M for the same period.
AtaiBeckley's rule of 40 is -11649% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AtaiBeckley's rule of X is -3579% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AtaiBeckley and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -85% | XXX | -48% | XXX | XXX | XXX |
| EBITDA Margin | -3367% | XXX | -3367% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -11649% | XXX | -3452% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3579% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18005% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33271% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AtaiBeckley acquired XXX companies to date.
Last acquisition by AtaiBeckley was XXXXXXXX, XXXXX XXXXX XXXXXX . AtaiBeckley acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was AtaiBeckley founded? | AtaiBeckley was founded in 2020. |
| Where is AtaiBeckley headquartered? | AtaiBeckley is headquartered in United States of America. |
| How many employees does AtaiBeckley have? | As of today, AtaiBeckley has 63 employees. |
| Who is the CEO of AtaiBeckley? | AtaiBeckley's CEO is Mr. Srinivas G. Rao, M.D.,PhD. |
| Is AtaiBeckley publicy listed? | Yes, AtaiBeckley is a public company listed on NAS. |
| What is the stock symbol of AtaiBeckley? | AtaiBeckley trades under ATAI ticker. |
| When did AtaiBeckley go public? | AtaiBeckley went public in 2021. |
| Who are competitors of AtaiBeckley? | Similar companies to AtaiBeckley include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AtaiBeckley? | AtaiBeckley's current market cap is $1.4B |
| What is the current revenue of AtaiBeckley? | AtaiBeckley's last 12 months revenue is $3.0M. |
| What is the current revenue growth of AtaiBeckley? | AtaiBeckley revenue growth (NTM/LTM) is -85%. |
| What is the current EV/Revenue multiple of AtaiBeckley? | Current revenue multiple of AtaiBeckley is 412.4x. |
| Is AtaiBeckley profitable? | Yes, AtaiBeckley is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AtaiBeckley? | AtaiBeckley's last 12 months EBITDA is -$101M. |
| What is AtaiBeckley's EBITDA margin? | AtaiBeckley's last 12 months EBITDA margin is -3367%. |
| What is the current EV/EBITDA multiple of AtaiBeckley? | Current EBITDA multiple of AtaiBeckley is -12.2x. |
| What is the current FCF of AtaiBeckley? | AtaiBeckley's last 12 months FCF is -$84.0M. |
| What is AtaiBeckley's FCF margin? | AtaiBeckley's last 12 months FCF margin is -2796%. |
| What is the current EV/FCF multiple of AtaiBeckley? | Current FCF multiple of AtaiBeckley is -14.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
